SDZ HTF 919 stimulates canine colonic motility and transit in vivo

Adrienne Nguyen, Michael Camilleri, Louis J. Kost, Alejandro Metzger, Michael G. Sarr, Russell B. Hanson, Sara L. Fett, Alan R. Zinsmeister

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Effects of the nonbenzamide 5-hydroxytryptamine, agonist SDZ HTF 919 on gastrointestinal motility are unclear. Our aim was to assess the in vivo effects on gastrointestinal and colonic transit of radiolabeled residue and on colonic phasic contractility. In six female dogs, transit was measured over a period of 2 days by radioscintigraphy and colonic motility was measured by pneumohydraulic perfusion manometry of the proximal and distal colon. SDZ HTF 919 was administered initially by bolus i.v. infusion, followed by s.c. injection 8 and 16 hr later. Doses tested were 0.03, 0.1 and 0.3 mg/kg, and isotonic saline and vehicle served as controls in each dog. Stomach and small bowel transit was not significantly altered by SDZ HTF 919. Overall, i.v. SDZ HTF 919 accelerated colonic transit during the first 1 hr, compared with controls. These effects were significant even with the lowest dose of SDZ HTF 919. Responses to higher infusion doses were more variable. SDZ HTF 919 did not cause significant changes in quantitative pressure indices, such as amplitude or motor index, in the small bowel or colon. Prolonged postprandial colonic contractions, each lasting >30 sec, were noted after each i.v. agent and were significantly more frequent with the 0.03 mg/kg dose than with control (vehicle) treatment. Thus, SDZ HTF 919 accelerates canine colonic transit in vivo during the first 1 hr after i.v. administration. SDZ HTF 919 appears to be a promising agent for stimulation of mammalian colonic transit.

Original languageEnglish (US)
Pages (from-to)1270-1276
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume280
Issue number3
StatePublished - Mar 1997

Fingerprint

Canidae
Colon
Dogs
Gastrointestinal Transit
Serotonin Receptor Agonists
Gastrointestinal Motility
tegaserod
Manometry
Stomach
Perfusion
Pressure
Injections

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nguyen, A., Camilleri, M., Kost, L. J., Metzger, A., Sarr, M. G., Hanson, R. B., ... Zinsmeister, A. R. (1997). SDZ HTF 919 stimulates canine colonic motility and transit in vivo. Journal of Pharmacology and Experimental Therapeutics, 280(3), 1270-1276.

SDZ HTF 919 stimulates canine colonic motility and transit in vivo. / Nguyen, Adrienne; Camilleri, Michael; Kost, Louis J.; Metzger, Alejandro; Sarr, Michael G.; Hanson, Russell B.; Fett, Sara L.; Zinsmeister, Alan R.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 3, 03.1997, p. 1270-1276.

Research output: Contribution to journalArticle

Nguyen, A, Camilleri, M, Kost, LJ, Metzger, A, Sarr, MG, Hanson, RB, Fett, SL & Zinsmeister, AR 1997, 'SDZ HTF 919 stimulates canine colonic motility and transit in vivo', Journal of Pharmacology and Experimental Therapeutics, vol. 280, no. 3, pp. 1270-1276.
Nguyen, Adrienne ; Camilleri, Michael ; Kost, Louis J. ; Metzger, Alejandro ; Sarr, Michael G. ; Hanson, Russell B. ; Fett, Sara L. ; Zinsmeister, Alan R. / SDZ HTF 919 stimulates canine colonic motility and transit in vivo. In: Journal of Pharmacology and Experimental Therapeutics. 1997 ; Vol. 280, No. 3. pp. 1270-1276.
@article{38d2df72bca74d04861c053cf0ffacf2,
title = "SDZ HTF 919 stimulates canine colonic motility and transit in vivo",
abstract = "Effects of the nonbenzamide 5-hydroxytryptamine, agonist SDZ HTF 919 on gastrointestinal motility are unclear. Our aim was to assess the in vivo effects on gastrointestinal and colonic transit of radiolabeled residue and on colonic phasic contractility. In six female dogs, transit was measured over a period of 2 days by radioscintigraphy and colonic motility was measured by pneumohydraulic perfusion manometry of the proximal and distal colon. SDZ HTF 919 was administered initially by bolus i.v. infusion, followed by s.c. injection 8 and 16 hr later. Doses tested were 0.03, 0.1 and 0.3 mg/kg, and isotonic saline and vehicle served as controls in each dog. Stomach and small bowel transit was not significantly altered by SDZ HTF 919. Overall, i.v. SDZ HTF 919 accelerated colonic transit during the first 1 hr, compared with controls. These effects were significant even with the lowest dose of SDZ HTF 919. Responses to higher infusion doses were more variable. SDZ HTF 919 did not cause significant changes in quantitative pressure indices, such as amplitude or motor index, in the small bowel or colon. Prolonged postprandial colonic contractions, each lasting >30 sec, were noted after each i.v. agent and were significantly more frequent with the 0.03 mg/kg dose than with control (vehicle) treatment. Thus, SDZ HTF 919 accelerates canine colonic transit in vivo during the first 1 hr after i.v. administration. SDZ HTF 919 appears to be a promising agent for stimulation of mammalian colonic transit.",
author = "Adrienne Nguyen and Michael Camilleri and Kost, {Louis J.} and Alejandro Metzger and Sarr, {Michael G.} and Hanson, {Russell B.} and Fett, {Sara L.} and Zinsmeister, {Alan R.}",
year = "1997",
month = "3",
language = "English (US)",
volume = "280",
pages = "1270--1276",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - SDZ HTF 919 stimulates canine colonic motility and transit in vivo

AU - Nguyen, Adrienne

AU - Camilleri, Michael

AU - Kost, Louis J.

AU - Metzger, Alejandro

AU - Sarr, Michael G.

AU - Hanson, Russell B.

AU - Fett, Sara L.

AU - Zinsmeister, Alan R.

PY - 1997/3

Y1 - 1997/3

N2 - Effects of the nonbenzamide 5-hydroxytryptamine, agonist SDZ HTF 919 on gastrointestinal motility are unclear. Our aim was to assess the in vivo effects on gastrointestinal and colonic transit of radiolabeled residue and on colonic phasic contractility. In six female dogs, transit was measured over a period of 2 days by radioscintigraphy and colonic motility was measured by pneumohydraulic perfusion manometry of the proximal and distal colon. SDZ HTF 919 was administered initially by bolus i.v. infusion, followed by s.c. injection 8 and 16 hr later. Doses tested were 0.03, 0.1 and 0.3 mg/kg, and isotonic saline and vehicle served as controls in each dog. Stomach and small bowel transit was not significantly altered by SDZ HTF 919. Overall, i.v. SDZ HTF 919 accelerated colonic transit during the first 1 hr, compared with controls. These effects were significant even with the lowest dose of SDZ HTF 919. Responses to higher infusion doses were more variable. SDZ HTF 919 did not cause significant changes in quantitative pressure indices, such as amplitude or motor index, in the small bowel or colon. Prolonged postprandial colonic contractions, each lasting >30 sec, were noted after each i.v. agent and were significantly more frequent with the 0.03 mg/kg dose than with control (vehicle) treatment. Thus, SDZ HTF 919 accelerates canine colonic transit in vivo during the first 1 hr after i.v. administration. SDZ HTF 919 appears to be a promising agent for stimulation of mammalian colonic transit.

AB - Effects of the nonbenzamide 5-hydroxytryptamine, agonist SDZ HTF 919 on gastrointestinal motility are unclear. Our aim was to assess the in vivo effects on gastrointestinal and colonic transit of radiolabeled residue and on colonic phasic contractility. In six female dogs, transit was measured over a period of 2 days by radioscintigraphy and colonic motility was measured by pneumohydraulic perfusion manometry of the proximal and distal colon. SDZ HTF 919 was administered initially by bolus i.v. infusion, followed by s.c. injection 8 and 16 hr later. Doses tested were 0.03, 0.1 and 0.3 mg/kg, and isotonic saline and vehicle served as controls in each dog. Stomach and small bowel transit was not significantly altered by SDZ HTF 919. Overall, i.v. SDZ HTF 919 accelerated colonic transit during the first 1 hr, compared with controls. These effects were significant even with the lowest dose of SDZ HTF 919. Responses to higher infusion doses were more variable. SDZ HTF 919 did not cause significant changes in quantitative pressure indices, such as amplitude or motor index, in the small bowel or colon. Prolonged postprandial colonic contractions, each lasting >30 sec, were noted after each i.v. agent and were significantly more frequent with the 0.03 mg/kg dose than with control (vehicle) treatment. Thus, SDZ HTF 919 accelerates canine colonic transit in vivo during the first 1 hr after i.v. administration. SDZ HTF 919 appears to be a promising agent for stimulation of mammalian colonic transit.

UR - http://www.scopus.com/inward/record.url?scp=0030972047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030972047&partnerID=8YFLogxK

M3 - Article

VL - 280

SP - 1270

EP - 1276

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -